Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVSX6O)

Drug Name
Tebipenem Drug Info
Synonyms Tebipenem [INN]
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Phase 3 [1]
Nicotine dependence 6C4A.2 Phase 2 [2]
Obesity 5B81 Phase 2 [2]
Cross-matching ID
PubChem CID
9800194
CAS Number
CAS 161715-21-5
TTD Drug ID
DMVSX6O

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cannabinoid receptor 1 (CB1) DTT CNR1 2.907 4.667 2.982 3.678
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Urinary tract infection
ICD Disease Classification GC08
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cannabinoid receptor 1 (CB1) DTT CNR1 5.59E-02 -0.22 -0.45
Cannabinoid receptor 1 (CB1) DTT CNR1 7.68E-01 -0.06 -0.46
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03788967) Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (ADAPT-PO). U.S. National Institutes of Health.
2 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.